BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25916083)

  • 1. Diffusion-weighted whole body imaging with background body signal suppression/T2 image fusion is negative for patients with intraductal papillary mucinous neoplasm.
    Tomizawa M; Shinozaki F; Motoyoshi Y; Sugiyama T; Yamamoto S; Ishige N
    Hepatogastroenterology; 2015; 62(138):463-5. PubMed ID: 25916083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Added value of diffusion-weighted imaging to MR cholangiopancreatography with unenhanced mr imaging for predicting malignancy or invasiveness of intraductal papillary mucinous neoplasm of the pancreas.
    Kang KM; Lee JM; Shin CI; Baek JH; Kim SH; Yoon JH; Han JK; Choi BI
    J Magn Reson Imaging; 2013 Sep; 38(3):555-63. PubMed ID: 23390008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion-weighted magnetic resonance imaging for evaluating the histological degree of malignancy in patients with intraductal papillary mucinous neoplasm.
    Ogawa T; Horaguchi J; Fujita N; Noda Y; Kobayashi G; Ito K; Koshita S; Kanno Y; Masu K; Sugita R
    J Hepatobiliary Pancreat Sci; 2014 Nov; 21(11):801-8. PubMed ID: 25082473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MR evaluation of breast lesions obtained by diffusion-weighted imaging with background body signal suppression (DWIBS) and correlations with histological findings.
    Moschetta M; Telegrafo M; Rella L; Capolongo A; Stabile Ianora AA; Angelelli G
    Magn Reson Imaging; 2014 Jul; 32(6):605-9. PubMed ID: 24721005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of DWIBS/T2 image fusion and PET/CT for the diagnosis of cancer in the abdominal cavity.
    Tomizawa M; Shinozaki F; Uchida Y; Uchiyama K; Tanaka S; Sunaoshi T; Kano D; Sugiyama E; Shite M; Haga R; Fukamizu Y; Fujita T; Kagayama S; Hasegawa R; Shirai Y; Motoyoshi Y; Sugiyama T; Yamamoto S; Ishige N
    Exp Ther Med; 2017 Oct; 14(4):3754-3760. PubMed ID: 29042975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Another dimension in magnetic resonance cholangiopancreatography: comparison of 2- and 3-dimensional magnetic resonance cholangiopancreatography for the evaluation of intraductal papillary mucinous neoplasm of the pancreas.
    Yoon LS; Catalano OA; Fritz S; Ferrone CR; Hahn PF; Sahani DV
    J Comput Assist Tomogr; 2009; 33(3):363-8. PubMed ID: 19478628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification.
    Serikawa M; Sasaki T; Fujimoto Y; Kuwahara K; Chayama K
    J Clin Gastroenterol; 2006 Oct; 40(9):856-62. PubMed ID: 17016145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Main pancreatic duct intraductal papillary mucinous neoplasms: accuracy of MR imaging in differentiation between benign and malignant tumors compared with histopathologic analysis.
    Manfredi R; Graziani R; Motton M; Mantovani W; Baltieri S; Tognolini A; Crippa S; Capelli P; Salvia R; Pozzi Mucelli R
    Radiology; 2009 Oct; 253(1):106-15. PubMed ID: 19703865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gadolinium injection on diffusion-weighted imaging with background body signal suppression (DWIBS) imaging of breast lesions.
    Moschetta M; Telegrafo M; Rella L; Stabile Ianora AA; Angelelli G
    Magn Reson Imaging; 2014 Dec; 32(10):1242-6. PubMed ID: 25127984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The carcinoembryonic antigen level in pancreatic juice and mural nodule size are predictors of malignancy for branch duct type intraductal papillary mucinous neoplasms of the pancreas.
    Hirono S; Tani M; Kawai M; Okada K; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
    Ann Surg; 2012 Mar; 255(3):517-22. PubMed ID: 22301608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of incidental branch-duct intraductal papillary mucinous neoplasms of the pancreas: A study with magnetic resonance imaging cholangiopancreatography.
    Girometti R; Pravisani R; Intini SG; Isola M; Cereser L; Risaliti A; Zuiani C
    World J Gastroenterol; 2016 Nov; 22(43):9562-9570. PubMed ID: 27920477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parametrial invasion in cervical cancer: fused T2-weighted imaging and high-b-value diffusion-weighted imaging with background body signal suppression at 3 T.
    Park JJ; Kim CK; Park SY; Park BK
    Radiology; 2015 Mar; 274(3):734-41. PubMed ID: 25299787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
    Michaels PJ; Brachtel EF; Bounds BC; Brugge WR; Pitman MB
    Cancer; 2006 Jun; 108(3):163-73. PubMed ID: 16550572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Branch duct-intraductal papillary mucinous neoplasms (BD-IPMNs): an MRI-based radiomic model to determine the malignant degeneration potential.
    Flammia F; Innocenti T; Galluzzo A; Danti G; Chiti G; Grazzini G; Bettarini S; Tortoli P; Busoni S; Dragoni G; Gottin M; Galli A; Miele V
    Radiol Med; 2023 Apr; 128(4):383-392. PubMed ID: 36826452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
    Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
    Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas.
    Uehara H; Nakaizumi A; Ishikawa O; Iishi H; Tatsumi K; Takakura R; Ishida T; Takano Y; Tanaka S; Takenaka A
    Gut; 2008 Nov; 57(11):1561-5. PubMed ID: 18477671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SLC2A1/GLUT1 expression in mural nodules of intraductal papillary mucinous neoplasm of the pancreas.
    Oda Y; Aishima S; Shindo K; Fujino M; Mizuuchi Y; Hattori M; Miyazaki T; Tanaka M; Oda Y
    Hum Pathol; 2017 Jul; 65():71-78. PubMed ID: 28412205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic juice cytology in the diagnosis of intraductal papillary mucinous neoplasm of the pancreas: significance of sampling by peroral pancreatoscopy.
    Yamaguchi T; Shirai Y; Ishihara T; Sudo K; Nakagawa A; Ito H; Miyazaki M; Nomura F; Saisho H
    Cancer; 2005 Dec; 104(12):2830-6. PubMed ID: 16287152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
    Mandai K; Uno K; Yasuda K
    Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.